Is Bayer headed for a breakup?

Bayer AG's decision to reach outside the company to bring in Thermo Fisher's Marijn Dekkers as its new CEO has the analysts buzzing about the likelihood of a substantial restucturing at the drug and chemical giant. "It looks like Bayer is getting prepared for corporate transformation," UBS AG analyst Fabian Wenner tells Bloomberg. "Dekkers is an expert in corporate restructuring. By focusing on health care, investors could have more visibility on each single element." Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.